COST-EFFECTIVENESS ANALYSIS OF LURASIDONE AND OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA

被引：0
|
作者：
Priyadarshini, M. [1 ]
Hay, J. W. [1 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1380
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMH40
引用
下载
收藏
页码：A188 / A189
页数：2
相关论文
共 50 条
  • [41] A COST-EFFECTIVENESS ANALYSIS OF THE LONG-ACTING ANTISPYCHOTIC DRUGS PALIPERIDONE PALMITATE, OLANZAPINE PAMOATE AND RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA IN FINLAND
    Einarson, T. R.
    Pudas, H.
    Zilbershtein, R.
    Jensen, R.
    Nielsen, A. T.
    Piwko, C.
    Hemels, M.
    Vincente, C.
    VALUE IN HEALTH, 2012, 15 (07) : A337 - A338
  • [42] EFFICACY, SAFETY AND COST-EFFECTIVENESS OF ARIPIPRAZOLE COMPARED TO OLANZAPINE FOR SCHIZOPHRENIA: SYSTEMATIC REVIEW AND META-ANALYSIS
    Santos, A. S.
    Godoi, I. P.
    Guerra-Junior, A. A.
    Acurcio, F. A.
    Brandao, C. M.
    VALUE IN HEALTH, 2017, 20 (05) : A301 - A301
  • [43] Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia - A randomized controlled trial
    Rosenheck, R
    Perlick, D
    Bingham, S
    Liu-Mares, W
    Collins, J
    Warren, S
    Leslie, D
    Allan, E
    Campbell, EC
    Caroff, S
    Corwin, J
    Davis, L
    Douyon, R
    Dunn, L
    Evans, D
    Frecska, E
    Grabowski, J
    Graeber, D
    Herz, L
    Kwon, K
    Lawson, W
    Mena, F
    Sheikh, J
    Smelson, D
    Smith-Gamble, V
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (20): : 2693 - 2702
  • [44] Using the net-benefit regression approach to compare the cost-effectiveness of haloperidol, olanzapine and risperidone in the treatment of schizophrenia
    De Ridder, A.
    De Graeve, D.
    VALUE IN HEALTH, 2007, 10 (06) : A295 - A295
  • [45] COST-EFFECTIVENESS OF PALIPERIDONE PALMITATE FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY
    Zeidler, J.
    Mahlich, J. C.
    Greiner, W.
    Heres, S.
    VALUE IN HEALTH, 2013, 16 (07) : A547 - A547
  • [46] RETURNING TO THE ISSUE OF THE COST-EFFECTIVENESS OF ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA
    Ohlsen, Ruth
    Taylor, David
    Tandon, Kopal
    Aitchison, Katherine
    CLINICAL NEUROPSYCHIATRY, 2008, 5 (04): : 184 - 194
  • [47] COST-EFFECTIVENESS OF PALIPERIDONE PALMITATE FOR THE TREATMENT OF SCHIZOPHRENIA IN MEXICO
    Reyes-Lopez, A.
    Querol, J.
    VALUE IN HEALTH, 2011, 14 (07) : A561 - A561
  • [48] Cost effectiveness model comparing fast dissolving olanzapine and conventional olanzapine tablets in the treatment of schizophrenia
    Ozsogut, B.
    Saylan, M.
    VALUE IN HEALTH, 2006, 9 (06) : A314 - A314
  • [49] Cost-effectiveness of olanzapine as a first-line treatment: A response to comment
    Tunis, Sandra L.
    Faries, Douglas E.
    Nyhuis, Allen W.
    Kinon, Bruce J.
    Ascher-Svanum, Haya
    Lilly, Eli
    Aquila, Ralph
    VALUE IN HEALTH, 2006, 9 (05) : 358 - 358
  • [50] The Cost-Effectiveness of Olanzapine Treatment for Agitation and Psychosis in Alzheimer's Disease
    Kirbaeh, Stephanie E.
    Simpson, Kit N.
    Nietert, Paul J.
    Mintzer, Jacobo E.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2008, 16 (03): : A71 - A72
12345